Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q1 2023 · 10-Q
Revenue—
Net Income-$1.34M-$1.34MN/M vs Q1 2022 EPS Diluted-$1.39-$1.39no prior Q1 2022 on file Operating Income-$521,258N/M Operating Cash Flow-$562,573N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end